Volitionrx (VNRX) Stock News

VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, reported its Q2 2025 financial results and provided a business update. The company recorded $0.4 million in revenue for Q2, achieving 15% growth in H1 2025 compared to the previous year. Net loss decreased by 11% for Q2 and 24% for H1 year-over-year.

The company is actively pursuing commercialization of its Nu.Q® platform in human diagnostics, engaging in discussions with over ten companies. VolitionRx expects to sign its first human diagnostics agreement this quarter. Cash position stood at $2.3 million as of June 30, 2025, with an additional $1.2 million raised post-quarter through a registered direct offering.

VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Second Quarter 2025 Earnings Conference Call and Business Update for Friday, August 15, 2025, at 8:30 a.m. Eastern Time. The call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and CEO), Terig Hughes (CFO), and Dr. Andrew Retter (Chief Medical Officer).

The conference call will be accessible via multiple channels, including toll-free numbers for U.S., Canada, and U.K. participants, as well as a live audio webcast. A replay will be available until August 29, 2025. The event will cover Q2 2025 financial results and provide updates on recent developments and upcoming milestones.

VolitionRx (NYSE American: VNRX), a multi-national epigenetics company, has announced a $1.21 million registered direct offering through the sale of common stock and warrants. The offering includes 156,250 shares to company insiders at $0.64 per share, and 1,734,375 shares with accompanying warrants to existing stockholders at the same price.

The warrants allow purchase of up to 1,734,375 additional shares at $0.768 per share, exercisable immediately and expiring in five years. If fully exercised, the warrants could generate an additional $1.3 million. The offering is expected to close around August 5, 2025. Proceeds will support research, product development, clinical studies, and commercialization efforts.

VolitionRx (NYSE AMERICAN: VNRX) reported significant progress in its Nu.Q® Discover program, which has an estimated $200 million annual addressable market. The program now serves over 20 global clients with 14 state-of-the-art immunoassays for epigenetic profiling.

The company's technology was validated in a peer-reviewed publication in the Journal of Biological Chemistry. The largest ongoing project involves a longitudinal Phase 1/2b study expected to complete in 2026, with projected revenue in the hundreds of thousands of dollars.

Volition is exploring co-marketing partnerships and anticipates signing new deals in the coming months, with potential for multi-million dollar partnerships if Nu.Q® assays advance to companion diagnostic use.

VolitionRx (NYSE AMERICAN: VNRX) has achieved a significant breakthrough in medical diagnostics by developing a lateral flow test that can quantify nucleosomes in whole venous blood within minutes. The company conducted a blinded study under the SUMMIT program, testing blood samples from 25 hospital patients in Intensive Care and Emergency Departments.

The new test shows strong correlation with Volition's established Nu.Q® nucleosome assay, enabling rapid detection of immune disruptions associated with conditions like sepsis. Unlike traditional positive/negative tests, this innovation provides quantitative results at the point-of-care, eliminating the need for laboratory processing.

The company plans to advance the SUMMIT program by developing a finger-prick version using capillary blood for broader applications.

VolitionRx (NYSE: VNRX) announced significant findings from a peer-reviewed clinical study of their Nu.Q® H3.1 biomarker in Critical Care. The large-scale study of 1,713 ICU patients demonstrated that Nu.Q® H3.1 is strongly associated with sepsis, organ dysfunction, and inflammatory responses. The research showed elevated Nu.Q® H3.1 levels in patients with acute kidney injury, disseminated intravascular coagulation, and acute respiratory distress syndrome. The study positions Nu.Q® H3.1 as a dynamic tool for prognostic enrichment and therapeutic monitoring, particularly in assessing NETosis, a biological process linked to critical illness. This development represents a significant opportunity for Volition in the multi-billion dollar critical care diagnostics market.

VolitionRx Limited announced two oral presentations featuring its Nu.Q® Vet Cancer Test at AMAMS 2025 in Thailand. The presentations showcase results from clinical studies conducted by Dr. Masahiko Sato in collaboration with FujiFilm Vet Systems. The first presentation explores the test's ability to differentiate between Canine Chronic Enteropathy and Gastrointestinal Lymphoma, while the second evaluates plasma nucleosome concentrations as a biomarker for canine nasal tumors. Dr. Sato, Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center in Japan, highlighted the test's potential as a valuable diagnostic tool. Kiyotaka Fujiwara, COO at Fujifilm Vet Systems, expressed optimism about the test's wider adoption following Dr. Sato's research and publications.

VolitionRx Limited (NYSE: VNRX) has announced a breakthrough in veterinary diagnostics with the successful detection of nucleosomes in cats, published in BMC Veterinary Research. This marks the first-ever detection of nucleosomes in felines, following previous successful applications in dogs and humans. The company's Nu.Q® technology shows promise for cancer screening in cats, particularly targeting feline lymphoma, the most common cancer in cats. The market opportunity is significant, with over 60 million cats in the U.S., of which 25% are seniors suitable for annual screening. The study confirms that H3.1 nucleosomes can be quantified from feline blood samples and establishes optimal collection protocols using EDTA tubes. Clinical trials for feline lymphoma detection are currently underway.

VolitionRx (NYSE: VNRX), a multi-national epigenetics company, reported its Q1 2025 financial results and business updates. The company recorded $0.25 million in revenue, up 44% year-over-year, while reducing monthly net cash burn to $1.4 million, a 50% reduction from Q1 2024.

Key highlights include ongoing confidential discussions with over ten companies for Nu.Q® platform commercialization in human diagnostics, with seven potential partners having a combined market value exceeding $600 billion. The company achieved its first revenue from CE-marked Nu.Q® NETs automated product sales in Europe during Q1 2025.

Financial position shows cash and equivalents of $2.6 million as of March 31, 2025, with additional funding of $4.3 million received in Q1 and a subsequent $6.25 million convertible loan note. VolitionRx aims to achieve cash neutrality for full-year 2025.